Price
$0.2611
Decreased by -9.97%
Dollar Volume
119.80 K
ADR%
19.54
Earnings Report Date (estimate)
Nov 28, 22 (-0.02)
Market Cap.
3.94 M
Shares Float
14.09 M
Shares Outstanding
15.09 M
Beta
1.60
Price / Earnings
-2.27
BPR
246.84
20D Range
0.02 0.44
50D Range
0.02 0.44
200D Range
0.02 0.65
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 9, 22 -0.01
Increased by +50.00%
-0.02
Increased by +50.00%
May 16, 22 -0.02
Increased by 0.00%
-0.02
Mar 29, 22 -0.60
Decreased by -5.90 K%
-0.30
Decreased by -100.00%
Nov 10, 21 -0.02
Increased by 0.00%
-0.02
Aug 4, 21 -0.02
Increased by +50.00%
-0.02
May 5, 21 -0.02
Decreased by -100.00%
-0.02
Mar 3, 21 -0.01
Increased by +80.00%
-0.02
Increased by +50.00%
Jul 31, 20 -0.02
Increased by +89.47%
-0.04
Increased by +50.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-6.41 M
Decreased by -76.71%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-2.07 M
Increased by +41.79%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-5.64 M
Decreased by -53.70%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-6.22 M
Decreased by -34.81%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-3.63 M
Decreased by -7.72%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-3.56 M
Decreased by -30.21%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-3.67 M
Increased by +29.19%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-4.62 M
Decreased by -352.68%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.